Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RNA-binding S12 protein, primarily known as the 30S ribosomal protein S12 (rpsL) in bacteria and 40S ribosomal protein S12 (RPS12) in humans, is a fundamental structural and functional component of the small ribosomal subunit [1, 16]. In bacteria, S12 is a key regulator of translational accuracy, coordinating the selection of aminoacyl-tRNAs and maintaining the fidelity of the decoding process within the 30S subunit [6, 13]. It is the primary molecular target for the aminoglycoside antibiotic streptomycin, which binds at the interface of S12 and 16S rRNA to stabilize a 'closed' ribosome conformation, leading to lethal mRNA misreading and inhibition of protein synthesis [6, 9]. Mutations in the rpsL gene are clinically significant as they represent the most common mechanism for high-level streptomycin resistance in pathogens such as Mycobacterium tuberculosis [3, 7]. In humans, the ortholog RPS12 is involved in ribosome biogenesis and has recently emerged as a potential therapeutic target in oncology due to its role in promoting Wnt/Wingless secretion and its overproduction in malignancies like triple-negative breast cancer and colorectal cancer [5, 12, 19].
Streptomycin binds to the 30S ribosomal subunit at the interface of the RNA-binding S12 protein and 16S rRNA, stabilizing the 'ram' (ribosome ambiguity) state; this reduces the selectivity of the decoding center, inducing the misreading of genetic code and the production of non-functional proteins [6, 7, 9, 13].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 30S ribosomal protein S12 (uS12) (S12).